Riluzole prodrugs and their use
US11052070B2 · kind B2 · utility
4Cited by
4References
3Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Nov 20, 2019 |
| Grant date | Jul 6, 2021 |
| Priority date | — |
| Expiry date | Nov 20, 2039 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K2300/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Pharmaceutical compositions of the invention include substituted riluzole prodrugs useful for the treatment of cancers including melanoma, breast cancer, brain cancer, and prostate cancer through the release of riluzole. Prodrugs of riluzole have enhanced stability to hepatic metabolism and are delivered into systemic circulation by oral administration, and then cleaved to release riluzole in the plasma via either an enzymatic or general biophysical release process.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.